Coya Therapeutics Management
Management criteria checks 0/4
Coya Therapeutics' CEO is Howard Berman, appointed in Jan 2020, has a tenure of 4.33 years. total yearly compensation is $1.32M, comprised of 44% salary and 56% bonuses, including company stock and options. directly owns 6.5% of the company’s shares, worth $7.67M. The average tenure of the management team and the board of directors is 1.7 years and 2.9 years respectively.
Key information
Howard Berman
Chief executive officer
US$1.3m
Total compensation
| CEO salary percentage | 44.0% |
| CEO tenure | 4.3yrs |
| CEO ownership | 6.5% |
| Management average tenure | 1.7yrs |
| Board average tenure | 2.9yrs |
Recent management updates
Recent updates
Coya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth Plans
Mar 26
Coya Therapeutics In Catbird Seat Following Dr. Reddy's Licensing Deal
Feb 13Coya Therapeutics: Interesting Early Data In CNS Diseases, Very Low Cash Position
Jan 13We Think Coya Therapeutics (NASDAQ:COYA) Needs To Drive Business Growth Carefully
Sep 06Here's Why We're Watching Coya Therapeutics' (NASDAQ:COYA) Cash Burn Situation
May 17CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$10m |
| Dec 31 2023 | US$1m | US$580k | -US$8m |
| Sep 30 2023 | n/a | n/a | -US$12m |
| Jun 30 2023 | n/a | n/a | -US$13m |
| Mar 31 2023 | n/a | n/a | -US$13m |
| Dec 31 2022 | US$598k | US$413k | -US$12m |
| Sep 30 2022 | n/a | n/a | -US$11m |
| Jun 30 2022 | n/a | n/a | -US$8m |
| Mar 31 2022 | n/a | n/a | -US$6m |
| Dec 31 2021 | US$390k | US$300k | -US$5m |
Compensation vs Market: Howard's total compensation ($USD1.32M) is above average for companies of similar size in the US market ($USD664.85K).
Compensation vs Earnings: Howard's compensation has increased whilst the company is unprofitable.
CEO
Howard Berman (49 yo)
4.3yrs
Tenure
US$1,317,200
Compensation
Dr. Howard Berman Ph D., has been the Chairman and Chief Executive Officer of Coya Therapeutics, Inc. since 2020. Dr. Berman gained corporate experience with increasing responsibilities and positions as a...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 4.3yrs | US$1.32m | 6.5% $ 7.7m | |
| President & Chief Medical Officer | less than a year | US$862.61k | 0% $ 0 | |
| CFO & COO | 2.2yrs | US$947.89k | 0.048% $ 56.6k | |
| Chief Technical Officer | 2.5yrs | no data | no data | |
| Senior Vice President of Regulatory Affairs | less than a year | no data | no data | |
| Head of Neuroinflammation Platform | no data | no data | no data | |
| Chief Business Development Officer | 1.2yrs | no data | no data |
1.7yrs
Average Tenure
62yo
Average Age
Experienced Management: COYA's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 4.3yrs | US$1.32m | 6.5% $ 7.7m | |
| Independent Director | 3.2yrs | US$63.75k | 0.068% $ 80.8k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2.9yrs | US$52.50k | 0.15% $ 181.6k | |
| Independent Director | 2.9yrs | US$55.00k | 0.014% $ 16.2k | |
| Clinical Advisor | less than a year | no data | no data | |
| Independent Director | 3yrs | US$53.75k | 0.068% $ 80.8k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | less than a year | no data | no data |
2.9yrs
Average Tenure
61yo
Average Age
Experienced Board: COYA's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.